TrialDrugs in R&D2018

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.

Tushar Garimella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.